CERN Accelerating science

მთავარი > CERN Experiments > MEDICIS Internal Notes

MEDICIS Internal Notes

ეძებე 44 ჩანაწერები:
ძებნის მინიშნებანი :: უბრალო ძებნა
დამატებულია/შესწორებულია: მდე:
დახარისხება: შედეგების ჩვენება: გამავალი ფორმატი:
უკანასკნელი დამატებები:
2025-11-25
09:09
Purification of Ce-134 from Ce-139 / Collins, Sean Michael (National Physical Laboratory (GB)) ; denis bacelar, ana (National Physical Laboratory) ; Haddad, Ferid (ARRONAX) ; Duchemin, Charlotte (CERN) ; Stora, Thierry (CERN)
For the treatment of cancers, targeted alpha-particle therapies (TAT) have become a significant field of interest due to their high cytotoxic dose delivered over short ranges to tumor regions whilst also reducing the dose delivered to neighboring healthy tissue. The alpha-emitting radionuclides of 225Ac, 227Th, 223Ra 212Pb and 211At are all actively researched for their therapeutic efficacy. [...]
MED-044.- Geneva : CERN, 2025 - 2. Fulltext: DOC;

დეტალური ჩანაწერი
2025-11-25
08:32
Pilot Clinical Study of Samarium-153-FAPI in Advanced Solid Tumors / Saeed, Shabana (Pakistan Institute of Engineering & Applied Sciences) ; khan, qaiser (pinstech) ; Ahmad, Naseer (NORI Atomic Energy Cancer Hospital) ; ur Rehman, Saif (NORI Atomic Energy Cancer Hospital) ; Rafique, Asif (NORI Atomic Energy Cancer Hospital)
New radio-bioconjugates targeting fibroblast activation protein (FAP), which is overexpressed in several malignancies, have been developed and have demonstrated significant promise in both preclinical and early clinical studies. These agents represent a new generation of radiopharmaceuticals [...]
MED-043.- Geneva : CERN, 2025 - 2. Fulltext: DOCX;

დეტალური ჩანაწერი
2024-12-09
10:57
Investigating the potential of Ac-225 labelled pharmaceuticals for Targeted Alpha Therapy: Pre-clinical & Clinical Evaluation / shabana, saed (Pakistan Institute of Engineering & Applied Sciences) ; khan, qaiser (PINSTECH)
Alpha emitters are increasingly recognized as promising candidates for the treatment of inoperable and drug-resistant tumors, owing to their high linear energy transfer (LET) of approximately 100 keV/μm and their short range of 50–100 μm, which corresponds to a few cell diameters. Among these alpha emitters, Actinium-225 (Ac-225) is considered a particularly favorable isotope for targeted alpha therapy due to its longer half-life and its ability to emit four alpha particles in its decay chain. [...]
MED-042.- Geneva : CERN, 2024 - 2. Fulltext: PDF;

დეტალური ჩანაწერი
2024-12-08
16:53
Detection of 225Ac produced in high-energy photo-spallation of 232Th / Lorusso, Giuseppe (National Physical Laboratory (GB)) ; Ivanov, Peter (NPL) ; Shearman, Robert (NPL)
This proposal is a crucial part of the broader effort to investigate isotope production using laser wake field accelerators (LWFAs). With this technique, a very short duration and powerful laser pulse is focussed through a gas jet or gas cell [...]
MED-041.- Geneva : CERN, 2024 - 2. Fulltext: DOC;

დეტალური ჩანაწერი
2024-12-08
16:35
Decay data for Ac-226 / Collins, Sean Michael (National Physical Laboratory (GB))
Targeted alpha-particle therapies (TAT) for cancer treatment is an area of significant research and development due to its promise for high efficacy and increased survival, due to its localized energy deposition. Actinium-225 is showing great potential for therapeutic use with many pre-clinical studies underway and significant investment across the globe for its production. [...]
MED-040.- Geneva : CERN, 2024 - 2. Fulltext: DOCX;

დეტალური ჩანაწერი
2024-07-01
07:55
Tb and Sc radionuclide separation and purification methods from solid targets and liquids for theranostic radiopharmaceutical development / Pajuste, Elina (University of Latvia (LV)) ; Mamis, Edgars (University of Latvia (LV)) ; Kalnina, Patricija (University of Latvia (LV))
There is a new radiochemistry lab being set up at the University of Latvia, dedicated to radionuclide studies with a particular interest in medical radionuclides. While the first studies with Sc isotopes are ongoing, the aim of the lab is to build competence also in radiolanthanides and alpha decay medical radionuclide purification and labeling studies. [...]
MED-039.- Geneva : CERN, 2024 - 2. Fulltext: DOCX;

დეტალური ჩანაწერი
2024-06-30
12:54
Pre-clinical proof-of-concept of a novel CCR5-targeted radioligand cancer therapy strategy / Garibotto, Valentina (HUG) ; Bejuy, O (HUG) ; Grotzky, Andrea (HUG) ; Montukur, G (UNIGE) ; Bois, Frederic (HUG) ; Hartley, O (UNIGE)
Triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC) are highly prevalent life- threatening diseases for which available treatment options are limited. Theranostic drugs use a ligand of a tumor cell molecular target in combination with different radiometals to both image and therapeutically target a tumor. [...]
MED-038.- Geneva : CERN, 2024 - 2. Fulltext: DOCX;

დეტალური ჩანაწერი
2023-12-03
23:21
AlphaMET (Metrology for Emerging Targeted Alpha Therapies) / Denis-Bacelar, Ana (NPL) ; Koole, Michel (KULeuven) ; Collins, Sean (NPL)
Targeted alpha therapy (TAT) is a rapidly growing cancer treatment modality, whereby alpha-emitting radiopharmaceuticals are combined with a targeting molecule to selectively seek tumours whilst minimising the damage to healthy cells. TAT is showing promising efficacy and increased survival in clinical trials for a variety of cancers; however, several unmet and unique measurement challenges remain a barrier to enable the safe and optimised implementation of emerging TATs. [...]
MED-037.- Geneva : CERN, 2023 - 3. Fulltext: DOC;

დეტალური ჩანაწერი
2023-12-03
23:13
Clinical and Pre-clinical Evaluation of Theranostic Pair (Terbium-161 and Terbium-155) for Imaging and Radionuclide Targeted Therapy of Tumors / Khan, Qaiser (PINSTECH)
The idea of theranostic approach is rapidly gaining momentum among the academia and practitioners in nuclear medicine community and there is considerable interest to commercially produce these isotopes for clinical applications. The approach combines diagnosis and therapy with suitable radiotracers [...]
MED-036.- Geneva : CERN, 2023 - 3. Fulltext: DOC;

დეტალური ჩანაწერი
2023-03-21
17:46
153SM-FAPI-46 RADIOLIGAND THERAPY WITH HIGH-MOLAR ACTIVITY 153SM / Prior, John (CHUV) ; Kratochwill, Clemens (Heidelberg University Hospital) ; Ooms, Marteen (SCK CEN) ; Cocolios, Thomas Elias (KU Leuven (BE)) ; Decristoforo, Clemens (INMUL)
New radiobioconjugates targeting fibroblast overexpressed in certain forms of cancers have recently been developed by the dept of nuclear medicine in Heidelberg and have shown important results in a range of different preclinical and clinical investigations. It demonstrates the potential of a new generation of radiopharmaceuticals targeting the Fibroblast Activation Protein (FAP), quinolone-based FAP inhibitors (FAPI) with a DOTA-chelator moiety and have shown potential benefits in both diagnosis and treatment, including patients presenting disseminated metastasis in lungs. [...]
MED-035.- Geneva : CERN, 2023 - 3. Fulltext: DOC;

დეტალური ჩანაწერი